AI needs a reality check

Marketing claims in AI rarely survive contact with reality. That’s because making real progress in healthcare is hard. To ...

OpenAI takes on Google with new AI designed to speed drug discovery

OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery, joining a ...

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...
China Daily Global Edition

AI-enabled pharmaceutical R&D market growing quickly

According to market consultancy Frost & Sullivan, the global AI-enabled pharmaceutical R&D market is projected to grow from ...

OpenAI takes on Google with new AI model aimed at drug discovery

The model will be available initially as a research preview to some of the company’s business customers, OpenAI said ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.